Catalent, Inc. (NASDAQ:CTLT) was downgraded by BidaskClub from a “buy” rating to a “hold” rating in a report issued on Tuesday.
Several other equities research analysts have also recently commented on CTLT. Bank of America Corporation reissued a “buy” rating and set a $38.00 target price (up previously from $37.00) on shares of Catalent in a report on Friday, July 21st. Zacks Investment Research cut Catalent from a “buy” rating to a “hold” rating in a report on Friday, August 18th. Piper Jaffray Companies reissued a “buy” rating and set a $45.00 target price on shares of Catalent in a report on Tuesday, August 29th. J P Morgan Chase & Co reissued a “buy” rating and set a $40.00 target price on shares of Catalent in a report on Tuesday, August 29th. Finally, Jefferies Group LLC reissued a “hold” rating and set a $38.00 target price (up previously from $35.00) on shares of Catalent in a report on Tuesday, August 29th. Five analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $42.11.
Catalent (NASDAQ CTLT) opened at $38.00 on Tuesday. Catalent has a 52-week low of $22.94 and a 52-week high of $43.39.
Catalent (NASDAQ:CTLT) last announced its earnings results on Monday, November 6th. The company reported $0.21 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.20 by $0.01. Catalent had a return on equity of 36.29% and a net margin of 10.02%. The firm had revenue of $543.90 million for the quarter, compared to analysts’ expectations of $490.75 million. During the same quarter in the previous year, the company earned $0.16 earnings per share. The firm’s quarterly revenue was up 23.0% compared to the same quarter last year.
TRADEMARK VIOLATION NOTICE: This story was posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this story on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.chaffeybreeze.com/2017/11/14/bidaskclub-downgrades-catalent-inc-ctlt-to-hold.html.
In other Catalent news, SVP Christine Dolan sold 1,594 shares of the company’s stock in a transaction on Tuesday, August 29th. The stock was sold at an average price of $38.75, for a total value of $61,767.50. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Acrospire Investment Management LLC increased its holdings in shares of Catalent by 72.2% in the second quarter. Acrospire Investment Management LLC now owns 3,100 shares of the company’s stock valued at $109,000 after buying an additional 1,300 shares in the last quarter. Quantbot Technologies LP increased its holdings in shares of Catalent by 110.7% in the second quarter. Quantbot Technologies LP now owns 3,434 shares of the company’s stock valued at $120,000 after buying an additional 1,804 shares in the last quarter. Fortaleza Asset Management Inc. bought a new position in shares of Catalent in the third quarter valued at $164,000. PNC Financial Services Group Inc. increased its holdings in shares of Catalent by 66.5% in the first quarter. PNC Financial Services Group Inc. now owns 6,070 shares of the company’s stock valued at $173,000 after buying an additional 2,425 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Catalent by 12.5% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,043 shares of the company’s stock valued at $177,000 after purchasing an additional 559 shares during the period.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Receive News & Ratings for Catalent Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc. and related companies with MarketBeat.com's FREE daily email newsletter.